Picard Medical Addresses Recent Stock Price Movements
Picard Medical, Inc. (NYSE American: PMI), the parent entity of SynCardia Systems LLC, known for pioneering the world’s first commercially approved total artificial heart, has recently commented on the fluctuations in its stock price. In a recent statement, Picard confirmed that there are no known undisclosed material changes regarding its operations or financial state that could explain the current volatility.
Continued Commitment to Operations
The leadership at Picard is focused on advancing their strategic goals and ensuring compliance with all legal obligations related to securities disclosures. Company representatives have emphasized their intent to navigate the fluctuating market conditions without compromising their vision and operational integrity.
Focus on Lifestyle and Health Innovation
In the field of medical technology, particularly in heart health, SynCardia has carved out a niche with its innovative product offerings. The company’s SynCardia Total Artificial Heart (STAH) represents a critical breakthrough for patients suffering from end-stage heart failure. By assuming all the heart's functions, the STAH enables patients to regain stability while awaiting a heart transplant.
Impact of the SynCardia Total Artificial Heart
Since its inception, the SynCardia Total Artificial Heart has been a beacon of hope for numerous patients. The device is not just the first of its kind to receive approval from both the FDA and Health Canada; it stands as the only total artificial heart currently available in North America. This pioneering status reflects a combination of rigorous research and a commitment to patient care.
Global Reach and Acceptance
With over 2,100 implants performed across 27 countries, the SynCardia Total Artificial Heart is the most widely used artificial heart globally. This extensive use has led to valuable clinical experiences and studies that underscore the device's effectiveness and reliability. Hospitals utilizing the STAH have reported improvements in patient quality of life during a critical phase of treatment.
Looking Towards the Future
As Picard Medical navigates the complexities of the healthcare market, its commitment to innovation remains unwavering. Collaborations and continued advancements in the field of artificial organs will likely play a significant role in the future of healthcare. Encouragingly, various research initiatives and development projects are underway to enhance the efficacy and accessibility of such technologies.
Investor Relations and Contact Information
For inquiries regarding the company and its journey, investors are encouraged to reach out to Eric Ribner, Managing Director at LifeSci Advisors LLC, via email at eric@lifesciadvisors.com. For additional information about Picard Medical and to explore the latest developments, you can reach out to their investor relations at IR@picardmedical.com. General inquiries can be directed to Brittany Lanza at blanza@syncardia.com.
Frequently Asked Questions
What is the recent statement from Picard Medical regarding its stock price?
Picard Medical has stated that it is not aware of any undisclosed material changes that could account for the recent volatility in its stock price.
What is the SynCardia Total Artificial Heart?
The SynCardia Total Artificial Heart is an implantable device that fully replaces the functions of a failing heart, providing a vital option for patients awaiting transplants.
How many SynCardia hearts have been implanted globally?
Over 2,100 SynCardia Total Artificial Hearts have been successfully implanted across 27 countries.
Is the SynCardia heart approved for use in the United States?
Yes, the SynCardia Total Artificial Heart is the only total artificial heart approved by both the FDA and Health Canada.
Who can I contact for more information about Picard Medical?
For investor inquiries, contact Eric Ribner at LifeSci Advisors at eric@lifesciadvisors.com. For general inquiries, reach out to Brittany Lanza at blanza@syncardia.com.
